Dr. Diba Kadivar | Inorganic Chemistry| Best Researcher Award
Dr. Diba Kadivar | Inorganic Chemistry| Ph. D. graduate in inorganic chemistry at chemistry and chemical engineering research center of iran , Iran
Dr. Diba Kadivar is a Ph.D. graduate in Inorganic Chemistry with extensive expertise in anticancer platinum complexes. She has been serving as a technical assistant at the Iranian Food and Drug Administration (IFDA) for over eight years, contributing to pharmaceutical research and regulatory affairs. Dr. Kadivar has conducted significant studies on the synthesis, characterization, and biological activity of novel platinum-based anticancer agents. Her research focuses on the impact of geometric isomerism and aliphatic N-substituted glycine derivatives on platinum complexes’ pharmacological properties. She has published multiple papers in reputed journals and actively collaborates on cancer cell line studies. Passionate about innovative drug discovery, she has contributed to the development of metal-based nanocomplexes for potential therapeutic applications. Dr. Kadivar remains committed to advancing medicinal inorganic chemistry through her research and collaborations, aiming to enhance the effectiveness of anticancer therapies while minimizing side effects.
Professional Profile :
Summary of Suitability for Award:
Dr. Diba Kadivar is a distinguished researcher in inorganic chemistry, specializing in anticancer platinum complexes. With a Ph.D. in inorganic chemistry and eight years of experience as a technical assistant at the Iranian Food and Drug Administration (IFDA), she has made notable contributions to the development of novel platinum-based anticancer agents. Her research focuses on the impact of geometric isomerism and the role of aliphatic N-substituted glycine derivatives in enhancing the biological activities of platinum complexes. She has published in reputable journals such as Elsevier and the Iranian Quarterly Journal of Chemical Communications, with a citation index of 18. Dr. Diba Kadivar’s innovative research on platinum-based anticancer drugs, scientific contributions, and expertise in inorganic medicinal chemistry make her highly suitable for the “Best Researcher Award.” Her work advances cancer treatment strategies, and her publications demonstrate scientific excellence and impact in medicinal chemistry.
🎓Education:
Dr. Diba Kadivar pursued her doctoral studies in Inorganic Chemistry, specializing in metal-based drug development and anticancer platinum complexes. Her academic journey has been marked by a strong foundation in medicinal chemistry, with a keen interest in exploring the role of isomerism in drug efficacy. During her Ph.D., she conducted extensive research on platinum complexes with glycine derivatives, focusing on their interaction with DNA and anticancer properties. Her work involved molecular docking, dynamic simulations, and in-vitro studies to evaluate the pharmacological potential of these compounds. Through her research, she contributed to the field of coordination chemistry and its applications in medicine. She has actively participated in international conferences, presenting her findings on novel platinum-based therapies. With a passion for drug discovery, Dr. Kadivar continues to apply her expertise in chemistry to enhance the effectiveness of anticancer agents.
🏢Work Experience:
Dr. Diba Kadivar has accumulated over eight years of professional experience as a technical assistant at the Iranian Food and Drug Administration (IFDA). In this role, she has been actively involved in regulatory affairs, pharmaceutical analysis, and drug quality control, ensuring the safety and efficacy of therapeutic compounds. Alongside her administrative responsibilities, she has played a vital role in cancer research, working in laboratory settings to study platinum-based anticancer agents. Her expertise extends to working with cancer and normal cell lines, contributing to drug screening and cytotoxicity assays. Additionally, she has been involved in synthesizing and characterizing novel platinum complexes, focusing on their pharmacological interactions. Dr. Kadivar also collaborates with academic institutions and research centers, aiming to bridge the gap between regulatory science and drug discovery. Her hands-on experience in both research and regulatory affairs makes her a key contributor to pharmaceutical advancements in Iran.
🏅Awards:
Dr. Diba Kadivar has been recognized for her contributions to inorganic and medicinal chemistry, particularly in the field of platinum-based anticancer research. She has received accolades for her pioneering work on the role of geometric isomerism in anticancer drug efficacy. Her research has been acknowledged at national and international scientific conferences, where she has been invited as a speaker and presenter. She has also played a key role in regulatory initiatives at the Iranian Food and Drug Administration, contributing to drug quality assurance and research-based policy-making. Additionally, her publications in esteemed journals such as Elsevier and the Iranian Quarterly Journal of Chemical Communications have received notable citations, highlighting her impact on the field. Dr. Kadivar’s dedication to advancing cancer therapy and pharmaceutical sciences continues to earn her recognition among her peers, further solidifying her reputation as an innovative researcher in medicinal inorganic chemistry.
🔬Research Focus:
Dr. Diba Kadivar’s research primarily revolves around the synthesis, characterization, and biological evaluation of platinum-based anticancer complexes. She investigates the impact of geometric isomerism on drug efficacy, focusing on how structural variations influence DNA interactions and cytotoxicity. Her studies explore novel ligand designs, particularly aliphatic N-substituted glycine derivatives, to enhance the pharmacological properties of platinum complexes. In addition to drug synthesis, she conducts in-vitro studies on cancer and normal cell lines to assess the cytotoxic potential of these compounds. She is also involved in molecular docking and dynamic simulations to predict drug interactions at the molecular level. Furthermore, she has worked on calcium, magnesium, copper, and zinc glycine edible nanocomplexes, aiming to develop biocompatible metal-based therapies. Through her interdisciplinary approach, Dr. Kadivar contributes to bridging chemistry and medicine, paving the way for new, targeted anticancer treatments with improved therapeutic outcomes.
Publication Top Notes:
Pharmacological properties of some 3-substituted indole derivatives, a concise overview
Authors: K. Nikoofar, D. Kadivar, S. Shirzadnia
Citations: 13
Year: 2014
Effect of geometric isomerism on the anticancer property of new platinum complexes with glycine derivatives as asymmetric N, O donate ligands against human cancer
Authors: D. Kadivar, M. E. Moghadam, B. Notash
Citations: 5
Year: 2024
Novel anticancer agents, Pt complex with 1-pyrrolidineacetic acid ligand: Synthesis, biological activity, DNA interaction, molecular docking, and dynamic study
Authors: D. Kadivar, M. E. Moghadam, M. Rezaeisadat
Year: 2025
